1. Home
  2. EVER vs NTLA Comparison

EVER vs NTLA Comparison

Compare EVER & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EverQuote Inc.

EVER

EverQuote Inc.

HOLD

Current Price

$27.37

Market Cap

929.5M

Sector

Technology

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.12

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVER
NTLA
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
929.5M
986.9M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
EVER
NTLA
Price
$27.37
$9.12
Analyst Decision
Strong Buy
Buy
Analyst Count
4
22
Target Price
$33.00
$19.83
AVG Volume (30 Days)
411.8K
4.5M
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
284.14
N/A
EPS
1.44
N/A
Revenue
$644,656,000.00
$57,528,000.00
Revenue This Year
$36.72
$1.96
Revenue Next Year
$13.44
N/A
P/E Ratio
$19.28
N/A
Revenue Growth
57.83
33.52
52 Week Low
$16.63
$5.90
52 Week High
$30.03
$28.25

Technical Indicators

Market Signals
Indicator
EVER
NTLA
Relative Strength Index (RSI) 61.64 40.70
Support Level $27.37 $9.15
Resistance Level $28.73 $9.68
Average True Range (ATR) 0.98 0.53
MACD -0.04 0.40
Stochastic Oscillator 65.65 54.69

Price Performance

Historical Comparison
EVER
NTLA

About EVER EverQuote Inc.

EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: